Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that the company’s Tryton Side Branch Stent has been used in 250 procedures to treat atherosclerotic lesions at a bifurcation in patients with heart disease.

“Bifurcation lesions have presented a challenge for cardiologists since the earliest days of angioplasty,” said Prof. David Foley of Beaumont Hospital in Dublin, Ireland (formerly the cardiac catheterization lab director at Thoraxcentre, Rotterdam). “Current approaches to treating these cases entail adaptation of available stents, leading to complexity and increased risk of peri-procedural complications and late restenosis. The Tryton Side Branch Stent offers a straightforward approach to first securing the side branch, while enabling trouble-free stenting of the main vessel using either a drug eluting or bare metal stent.

“Over the past two months, I have subjected the Tryton Stent to robust challenges in complex bifurcations and am happy to state that it has become an important tool for treating my patients with bifurcation lesions.”

“We’re pleased that the Tryton Side Branch Stent is helping physicians across Europe treat some of the most challenging interventional cases in cardiovascular disease,” said J. Greg Davis, president and CEO of Tryton Medical. “We look forward to demonstrating our innovative stent system at TCT later this month.”

Tryton at Transcatheter Cardiovascular Therapeutics (TCT) 2009

Tryton Medical will exhibit the Tryton Side Branch Stent System in booth 630 at this year’s Transcatheter Cardiovascular Therapeutics (TCT) Conference taking place in San Francisco Sept. 21 through 25, 2009.

http://www.trytonmedical.com/